What the AGP acquisition and restructuring means for Pakistani pharma

For some Pakistani pharmaceutical companies, the exit of foreign brands is an opportunity. AGP Ltd is one of those most actively trying to capitalize on the foreign players’ exits.

The Karachi-based pharmaceutical manufacturer, already one of the better-known names on the Pakistan Stock Exchange, is in the middle of a restructuring that would fold several businesses associated with the OBS Group into a single listed platform. The transaction brings together AGP, OBS AGP, OBS Pakistan and the substantive operations of OBS Pharma, the business that owns the former Bayer portfolio in Pakistan. In one stroke, AGP is seeking to simplify a corporate structure that had become increasingly complicated as the group bought portfolios from Sandoz, Viatris and Bayer over the past few years.

The legal mechanics are still subject to approvals. The scheme requires creditors’ and regulatory approvals and sanction by the Sindh High Court. Management has indicated that the arrangement is expected to become effective retrospectively from January 1, 2026, with final legal effectiveness expected by the last quarter of calendar year 2026. But financially, investors are already being asked to look at AGP as if the old structure has ended and a larger, more coherent pharmaceutical platform has taken its place.